COMMUNIQUÉS West-GlobeNewswire

Eurobio Scientific : Rapport Financier Annuel 2023

26/04/2024 - 17:40

Eurobio Scientific : Rapport Financier Annuel 2023 Pièce jointe EBS_RFA_2023

BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles

26/04/2024 - 17:30

PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 26 April 2024, 17:30 CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory [...]

BioSenic publie sur son site web le plan de restructuration soumis au tribunal des entreprises de Nivelles

26/04/2024 - 17:30

COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE Mont-Saint-Guibert, Belgique, le 26 avril 2024 à 17h30 CEST – BIOSENIC (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée dans les maladies auto- [...]

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

26/04/2024 - 15:23

Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities. The converted common stock is included in the company’s total 165 million outstanding shares. The Tevogen.ai [...]

Range Impact Transitions Two Executives to Graphium Biosciences Subsidiary as Part of Proposed Divestiture and Promotes Corporate Controller to Chief Financial Officer

26/04/2024 - 15:20

CLEVELAND, OHIO, April 26, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or “Company”), an impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in economically [...]

ONWARD® Medical annonce ses résultats financiers et opérationnels pour l’exercice 2023 et partage les faits qui ont marqué l’exercice 2024 à ce jour

26/04/2024 - 15:17

Dépôt auprès de la FDA d’une demande de classification du dispositif ARC-EX ® System basée sur les risques (demande « De Novo ») Levée de fonds de 20 millions d’euros Annonce des résultats préliminaires positifs de l’ [...]

HWH International Inc. enters into a joint venture to build its travel business in Asia

26/04/2024 - 15:15

Bethesda, MD, April 26, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“ HWH ”) (Nasdaq: HWH) announced today that it has entered into a joint venture through its subsidiary Health Wealth Happiness Pte Ltd. (“ HWHPL [...]

Capsa’s New NexPak Addresses Medication Administration Efficiencies In Correctional Care

26/04/2024 - 15:12

COLUMBUS, Ohio, April 26, 2024 (GLOBE NEWSWIRE) -- Addressing the medication requirements of incarcerated individuals in U.S. correctional facilities has grown more challenging, particularly due to understaffing among [...]

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26/04/2024 - 15:05

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and [...]

Ibogaine By David Dardashti Begins Inflammation Tests to Demonstrate Adequate Results

26/04/2024 - 15:02

Doctor Ashok Bharucha Proposes That Ibogaine Can Help Improve Immune System Functionality MIAMI, April 26, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti is taking proactive steps to prove the efficacy of ibogaine [...]

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

26/04/2024 - 15:00

ORION CORPORATION STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS 26 APRIL 2024 at 16.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

26/04/2024 - 14:30

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of [...]

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

26/04/2024 - 14:30

April 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) Worldwide rights [...]

QHSLab, Inc. Announces Preliminary Unaudited First Quarter Revenue Results

26/04/2024 - 14:30

WEST PALM BEACH, FL, April 26, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. ("the Company") (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based [...]

Exagen Inc. Announces Changes to the Board of Directors

26/04/2024 - 14:30

CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott [...]

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

26/04/2024 - 14:30

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from [...]

Nova Leap Health Corp. Announces Execution of Definitive Agreement

26/04/2024 - 14:20

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]

Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management

26/04/2024 - 14:00

Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX [...]

Neurosurgery Customer from Germany Orders Nexstim NBS System 5

26/04/2024 - 14:00

Press release, Helsinki, 26 April 2024 at 3 PM (EEST) Neurosurgery Customer from Germany Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new NBS System 5 from an [...]